Last reviewed · How we verify
Oral Calcitonin Tablets
Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss.
Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss. Used for Osteoporosis in postmenopausal women, Bone loss and fracture risk reduction.
At a glance
| Generic name | Oral Calcitonin Tablets |
|---|---|
| Also known as | rsCT tablets |
| Sponsor | Tarsa Therapeutics, Inc. |
| Drug class | Calcitonin receptor agonist |
| Target | Calcitonin receptor |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | Phase 3 |
Mechanism of action
Calcitonin is a peptide hormone that binds to calcitonin receptors expressed on osteoclasts, leading to their inactivation and apoptosis. This reduces bone resorption and helps maintain or increase bone mineral density. The oral formulation uses proprietary delivery technology to enable systemic absorption of this peptide hormone through the gastrointestinal tract.
Approved indications
- Osteoporosis in postmenopausal women
- Bone loss and fracture risk reduction
Common side effects
- Nausea
- Flushing
- Headache
- Gastrointestinal upset
Key clinical trials
- Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients (PHASE4)
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens (PHASE4)
- Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
- The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients (PHASE3)
- Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (PHASE4)
- The Effect of Sumatriptan and Placebo on CGRP Induced Headache (NA)
- A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) (PHASE1)
- A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Calcitonin Tablets CI brief — competitive landscape report
- Oral Calcitonin Tablets updates RSS · CI watch RSS
- Tarsa Therapeutics, Inc. portfolio CI